MONTREAL, Dec. 10, 2013 /CNW Telbec/ - NEOMED, a leading drug discovery
and development public-private partnership in Canada, today announced a
new collaboration with Johnson & Johnson Innovation, and its affiliate
Janssen Inc. Canada, to accelerate the transition of university and
biotechnology company early-stage research into potential treatments.
Through this collaboration, teams of experienced technical experts at
both the Johnson & Johnson Innovation Center in Boston, Massachusetts
and NEOMED will work together to identify and advance medically
important projects. These projects will come from NEOMED's network of
partnered academic institutions and biotechnology companies, as well as
from Canadian, US and international drug discovery groups.
"NEOMED welcomes the opportunity to work with the pharmaceutical
researchers at Johnson & Johnson Innovation in this innovative business
model," said Dr. Max Fehlmann, President and CEO of NEOMED and the
NEOMED Institute. "Johnson & Johnson Innovation has been a pioneer in
large Pharma external research and the reinvention of the drug
discovery enterprise. We look forward to their valuable contribution in
support of our mission of helping academia to efficiently translate
early innovations into high value drug candidates."
Johnson & Johnson Innovation is the third global pharmaceutical company
collaborator to join NEOMED since its founding in late 2012. The other
global pharmaceutical company partners are AstraZeneca and Pfizer.
About NEOMED and the NEOMED Institute
NEOMED was set up one year ago to support the transition of promising
drug discovery technologies and therapeutic approaches emerging from
academic and biotechnology companies, and to bring these emerging
therapeutics to IND or Phase II human proof-of-concept, which are
stages when the drug candidates become most attractive to the
biopharmaceutical companies. NEOMED is jointly funded by AstraZeneca,
Pfizer and the Ministère des Finances et de l'Économie du Québec.
NEOMED's sole focus is drug discovery, and preclinical and early
clinical drug development. It has a team of scientists with
industry-level expertise and capabilities ranging from medicinal
chemistry, drug target validation studies through animal pharmacology,
toxicology and clinical trials design and implementation.
NEOMED is established within the NEOMED Institute, a state-of-the-art
R&D facility in the Montreal Technoparc. The Institute acts as an
open-access drug discovery hub hosting drug discovery and development
research companies, providing a unique environment to foster
innovation, collaboration and creativity.
For more information, please visit: www.neomed.ca
For further information:
Mounia Azzi, PhD
Director, Scientific Affairs